Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes

被引:101
作者
Abbo, A.
Carmeli, Y.
Navon-Venezia, S.
Siegman-Igra, Y.
Schwaber, M. J.
机构
[1] Tel Aviv Med Ctr & Sch Med, Div Epidemiol, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Med Ctr & Sch Med, Div Infect Dis, Tel Aviv, Israel
关键词
D O I
10.1007/s10096-007-0371-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We conducted a retrospective matched cohort study to examine the impact of isolation of multi-drug-resistant (MDR) Acinetobacter baumannii on patient outcomes. Cases from whom MDR A. baumannii was isolated in a clinical culture (n=118) were compared with controls from whom MDR A. baumannii was not isolated (n=118). Cases and controls were matched according to ward, calendar month of hospitalization, and duration of hospitalization before culture. The following outcomes were compared in multivariable analysis: in-hospital mortality, length of stay, need for mechanical ventilation, and functional status at discharge. MDR A. baumannii was determined to be a pathogen in 72% of cases. In 36% of cases, the patient died, versus 21% of controls (odds ratio [OR] 2.21, 95% confidence interval [CI] 1.17-4.16, P=0.014). Median length of stay for surviving cases was 17 days, versus 11 for surviving controls (multiplicative effect 1.55, 95% CI 0.99-2.44, P=0.057). Fifty-two percent of cases required mechanical ventilation, versus 25% of controls (OR 3.72, 95% CI 1.91-7.25, P < 0.001); 60% of surviving cases were discharged with reduced functional status, versus 38% of controls (OR 4.4, 95% CI 1.66-11.61, P=0.003). In multivariable analysis, clinical isolation of MDR A. baumannii remained a significant predictor of mortality (OR 6.23, 95% CI 1.31-29.5, P=0.021), need for mechanical ventilation (OR 7.34, 95% CI 2.24-24.0, P < 0.001), and reduced functional status on discharge (OR 7.93, 95% CI 1.1-56.85, P=0.039). Thus, MDR A. baumannii acquisition is associated with severe adverse outcomes, including increased mortality, need for mechanical ventilation, and reduced functional status.
引用
收藏
页码:793 / 800
页数:8
相关论文
共 41 条
  • [2] Multidrug-resistant Acinetobacter baumannii
    Abbo, A
    Navon-Venezia, S
    Orly, HM
    Krichali, T
    Siegman-Igra, Y
    Carmeli, Y
    [J]. EMERGING INFECTIOUS DISEASES, 2005, 11 (01) : 22 - 29
  • [3] Trends in bacterial resistance to fluoroquinolones
    Acar, JF
    Goldstein, FW
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 : S67 - S73
  • [4] [Anonymous], 1996, Am J Infect Control, V24, P380
  • [5] EPIDEMIC BACTEREMIA DUE TO ACINETOBACTER-BAUMANNII IN 5 INTENSIVE-CARE UNITS
    BECKSAGUE, CM
    JARVIS, WR
    BROOK, JH
    CULVER, DH
    POTTS, A
    GAY, E
    SHOTTS, BW
    HILL, B
    ANDERSON, RL
    WEINSTEIN, MP
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1990, 132 (04) : 723 - 733
  • [6] Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients:: a matched cohort study
    Blot, S
    Vandewoude, K
    Colardyn, F
    [J]. INTENSIVE CARE MEDICINE, 2003, 29 (03) : 471 - 475
  • [7] Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
    Carmeli, Y
    Troillet, N
    Karchmer, AW
    Samore, MH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) : 1127 - 1132
  • [8] Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant enterococcus
    Carmeli, Y
    Eliopoulos, GM
    Samore, MH
    [J]. EMERGING INFECTIOUS DISEASES, 2002, 8 (08) : 802 - 807
  • [9] Bacteremia due to Acinetobacter baumannii epidemiology, clinical findings, and prognostic features
    Cisneros, JM
    Reyes, MJ
    Pachon, J
    Becerril, B
    Caballero, FJ
    GarciaGarmendia, JL
    Ortiz, C
    Cobacho, AR
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 22 (06) : 1026 - 1032
  • [10] *CLIN LAB STAND I, 2005, PERF ANT SUSC TEST 1